The focus of this project is on advancing tau-targeted immunotherapy and compounds that interfere with pathological processes mediated by tau.
Researchers at Neuroscience Research Australia (NeuRA) and University of New South Wales (UNSW) are inviting people with Mild Cognitive Impairment (MCI) or Subjective Cognitive Decline (SCD) to participate in a voluntary online research trial aiming to reduce the risk of dementia.
What is the MyCOACH Trial about?
This research aims to test the effectiveness of an e-learning and behaviour change course designed to support healthy brain ageing and reduce risk of dementia. The course is tailored for people reporting cognitive difficulties or changes. The trial runs for 12 weeks, with a follow up at 1 and 2 years afterwards.
What is involved in this research trial?
Interested volunteers will be asked to complete some eligibility checks to confirm this study is a good match. If you decide to take part you would:
MyCOACH e-learning group (“Intervention”): Volunteers in this group participate in the 12 week online MyCOACH program. This includes 6 e-learning chapters, as well as three phone consultations with a dietician and/or exercise physiologist, and a 3-month subscription to a brain training app.
Control Education group (“Control”): Volunteers in this group will receive information about cognitive health and risk factors for dementia. This group is important to be able to measure the effectiveness of the research. At the end of the study, volunteers in this “control” group can access the full MyCOACH e-learning course.
You may be eligible to participate in the MyCOACH Trial if you:
Expressions of interest
If you are interested or know someone who might be, please contact us for more information:
Phone: (02) 9399 1815
Research investigating the impacts of cognitive behavioural therapy and balance programs on fear of falling, funded by Mindgardens.
Falls and fear of falling affect many older people and can impose limitations upon daily activities. Over one third of community dwelling older people fall each year with about 15% of falls being injurious. However, two thirds of older people express a fear of falling during common daily activities, making it more common than falls itself. Fear of falling has been associated with needless restriction in physical and social activities, and subsequent deterioration of health and wellbeing.
Previous research has suggested that fear of falling can be reduced through cognitive behavioural therapy (CBT) and balance exercise programs. However, these face-to-face treatments are resource intensive and not readily accessible to people. Furthermore, the effects of these treatments on fear of falling are small and often do not last beyond the duration of the program.
By utilising technology and providing tailored physical activity guidance we are aiming to reduce a fear of falling in an accessible, efficient and lasting way.
A thee-arm randomised clinical trial will be conducted in 189 community-dwelling older adults with a substantial concern of falling. Participants will be randomly allocated into one of three groups in order to test whether a self-managed CBT intervention, alone or in combination with a graded balance activity program, can reduce concerns about falling in older adults when compared to usual care.
We are collaborating with the Black Dog institute to provide a home-based cognitive behavioural therapy program that addresses a fear of falling. We will also be utilising our cutting-edge balance program StandingTall to provide a graded balance program.
We know that having high blood pressure increases the chance that we will develop dementia and cognitive decline as we grow older but we are still trying to understand whether using blood pressure lowering treatments (antihypertensives) can help to prevent this. To explore the relationship between blood pressure, blood pressure lowering and cognition we will combine global data from the highest quality placebo-controlled trials of antihypertensive drugs. This project will deliver knowledge and targeted clinical recommendations for antihypertensive use to support reduction of dementia risk.